Marimastat
- Generic Name
- Marimastat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H29N3O5
- CAS Number
- 154039-60-8
- Unique Ingredient Identifier
- D5EQV23TDS
- Background
Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.
- Indication
For the treatment of various cancers
- Associated Conditions
- -
- Associated Therapies
- -
Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.
- Conditions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2008-01-09
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT00261391
- Locations
- ๐บ๐ธ
Childrens Hospital, Boston, Massachusetts, United States
Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- ILEX Oncology Services, Incorporated
- Registration Number
- NCT00002911
- Locations
- ๐บ๐ธ
Hematology Associates, Ltd., Phoenix, Arizona, United States
๐บ๐ธVincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States
๐บ๐ธUniversity of Connecticut Health Center, Farmington, Connecticut, United States
Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy
- Conditions
- First Posted Date
- 2004-04-14
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 334
- Registration Number
- NCT00003010
- Locations
- ๐บ๐ธ
CCOP - Carle Cancer Center, Urbana, Illinois, United States
๐บ๐ธSiouxland Hematology-Oncology, Sioux City, Iowa, United States
๐บ๐ธCCOP - Duluth, Duluth, Minnesota, United States
Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 555
- Registration Number
- NCT00003011
- Locations
- ๐จ๐ฆ
British Columbia Cancer Agency - Vancouver Island Cancer Centre, Victoria, British Columbia, Canada
๐จ๐ฆCross Cancer Institute, Edmonton, Alberta, Canada
๐จ๐ฆBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.